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Primary open-angle glaucoma (POAG), is a heritable common cause of blindness world-wide.
To identify risk loci, we conduct a large multi-ethnic meta-analysis of genome-wide asso-
ciation studies on a total of 34,179 cases and 349,321 controls, identifying 44 previously
unreported risk loci and confirming 83 loci that were previously known. The majority of loci
have broadly consistent effects across European, Asian and African ancestries. Cross-
ancestry data improve fine-mapping of causal variants for several loci. Integration of multiple
lines of genetic evidence support the functional relevance of the identified POAG risk loci and
highlight potential contributions of several genes to POAG pathogenesis, including SVEP1,
RERE, VCAM1, ZNF638, CLIC5, SLC2A12, YAP1, MXRA5, and SMAD6. Several drug compounds
targeting POAG risk genes may be potential glaucoma therapeutic candidates.
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Primary open-angle glaucoma (POAG) is the leading cause ofirreversible blindness globally1,2. The disease is character-ized by progressive optic nerve degeneration that is usually
accompanied by elevated intraocular pressure (IOP). Neuropro-
tective therapies are not available and current treatments are
limited to lowering IOP, which can slow disease progression at
early disease stages; however, over 50% of glaucoma is not diag-
nosed until irreversible optic nerve damage has occurred2,3.
POAG is highly heritable4,5, and previous genome-wide asso-
ciation studies (GWAS) have identified important loci associated
with POAG risk6–15. Despite this success, the POAG genetic
landscape remains incomplete and identification of additional risk
loci is required to further define contributing disease mechanisms
that could be targets of preventative therapies.
The majority of known risk loci for POAG have been identified
through GWAS in participants of European descent, followed by
replication in other ethnic populations. However, previous obser-
vational studies have shown that individuals of African ancestry,
followed by Latinos and Asians, have higher POAG disease burden
compared to those with European ancestry3,16–18, suggesting
important differences in genetic risk and highlighting the need to
compare the genetic architecture of these ethnic groups.
In this study, we report the results of a POAG multi-ethnic
meta-analysis on 34,179 cases and 349,321 controls, identifying
127 risk loci (44 not previously reported at genome-wide sig-
nificance levels for POAG). The identified risk loci have broadly
consistent effects across European, Asian, and African ancestries.
We show that combining GWAS data across ancestries improves
fine-mapping of the most likely causal variants for some loci. By
integrating multiple lines of genetic evidence we identify the most
likely causal genes, some of which might contribute to glaucoma
pathogenesis through biological mechanisms related to extra-
cellular matrix cell adhesion, intracellular chloride channels,
adipose metabolism, and YAP/HIPPO signaling.
Results
Discovery of previously unreported POAG risk loci in Eur-
opeans. We performed a four-stage meta-analysis (Fig. 1). In the
first stage, we conducted a fixed-effect meta-analysis of 16,677
POAG cases and 199,580 controls of European descent. The par-
ticipating studies are detailed in Supplementary Data 1. We iden-
tified 66 independent genome-wide significant (P < 5e-08) single
nucleotide polymorphisms (SNPs) (Supplementary Data 2), of
which 16 were not previously identified (i.e., uncorrelated with
previously reported SNPs). There was no evidence of inflation
due to population structure (linkage disequilibrium (LD) score
regression19 intercept 1.03, se= 0.01, Supplementary Fig. 1A).
Significant POAG risk loci in Asians and Africans. In the
second stage, we completed a fixed-effect meta-analysis of 6935
POAG cases and 39,588 controls of Asian descent, and a separate
fixed-effect meta-analysis of 3281 POAG cases and 2791 controls
of African ancestry (Supplementary Data 1). Ten loci were sig-
nificantly associated with POAG (P < 5e-8) in the meta-analysis
of Asian studies (Supplementary Data 3), all of which are known
POAG loci, and at least nominally (P < 0.05) associated with
the European meta-analysis. While only one of these loci had a
P < 0.05 in Africans, eight had consistent direction of effects.
For the African meta-analysis, one locus (rs16944405 within
IQGAP1) reached the genome-wide significance level (P= 3e-08).
This locus has not been previously reported for POAG, and in
this study, was not associated with POAG in Europeans
(P= 0.315) and Asians (P= 0.075) (Supplementary Data 3). The
LD score regression intercept was 0.99 (se= 0.009) for Asians
and 0.95 (se= 0.006) for Africans, suggesting that these results
are not influenced by population structure.
Consistent genetic effect across ancestries. As part of the second
stage, we replicated the stage 1 European Caucasian findings in an
independent dataset comprising 7,286 self-reported cases and
107,362 controls of European descent from the UK Biobank study
(UKBB) (Supplementary Data 1)20, as well as in the meta-
analyzed Asian and African datasets described above. We repli-
cated the European Caucasian results in each ancestry group
separately (Supplementary Data 2 and Supplementary Fig. 2),
followed by combining the three replication datasets in a fixed-
Stage 1: meta-analysis 





Stage 2: meta-analysis 
of POAG in different 
ancestries
Stage 3: meta analysis 
of stage 1 and stage 2
Stage 4: replication of 
stage 3 findings in 
23andMe
Europeans: 16,677 cases 
& 199,580 controls
Asians: 6,935 cases & 39,588 controls
Africans: 3,281 cases & 2,791 controls
Europeans: 7,286 cases & 107,362
Stage 1 + Stage 2:
 34,179 cases & 349,321 
controls
23andMe: 43,254 cases & 
1,471,118 controls
a) 66 genome-wide 
significant SNPs, 16 were 
novel;
b) LD score regression.
a) replicate Stage 1 results in each 
ancestry group separately;
b) replicate in Stage 2 meta-analysis: 
56 were nominally significant 
(P<0.05), and 37 after Bonferroni 
correction (P<7.6e-4);
c) high cross-ancestry concordance.
a) meta analysis of Stage 1 and 
Stage 2 identified 127 loci (44 novel);
b) cross-ancestry fine mapping;
c) investigate functional relevance by 
integrating multiple lines of evidence: 
eQTL and chromatin interaction, 
pathogenicity scores; gene/pathway 
analysis in MAGMA; TWAS analysis 
in MetaXcan, SMR, and FOCUS;
d) differential gene expression in eye 
tissues;
e) identify drug targets;
e) subgroup analysis in male/female 
and HTG/NTG.
120 replicated at P<0.05, 106 
after Bonferroni correction.
Fig. 1 Study design. This figure summarizes the four stages of this study, as well as the data resources and main analyses/results for each stage.
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effect meta-analysis (17,502 cases and 149,741 controls) to
maximize statistical power. Of the 66 significant loci in the
European Caucasian meta-analysis, 56 were nominally significant
(P < 0.05), and 37 after Bonferroni correction (P < 7.6e-04) in the
meta-analyzed replication cohort. The effect sizes had a Pearson
correlation coefficient (r)= 0.82 (Fig. 2).
There was moderately high cross-ancestry concordance both
for genome-wide significant loci and across the genome. For the
genome-wide significant SNPs, the European SNP effects were
correlated (Pearson correlation coefficient (r)= 0.68 [95%
confidence intervals (CIs) 0.38–0.97] and r= 0.44 [95% CIs
0.20–0.69]) with Asian and African ancestries, respectively
(Supplementary Fig. 2B, C). Of the 68 SNPs available in the
Asian meta-analysis, 60 (88%) showed the same direction of effect
as European Caucasians, and of the 66 SNPs available in the
African meta-analysis, 55 (83%) showed the same direction as
European Caucasians. The genetic correlation across the genome
estimated using the approach implemented in Popcorn v0.9.921
was even higher: r= 0.85 (95% CIs 0.70–1.00) for European-
Asian and r= 0.75 (95% CIs −0.93 to 2.43) for European-
African. Although the concordance amongst the top SNPs was
clear for the European-African comparison, larger sample sizes
will be required to narrow the CIs on the European-African
genome-wide correlation estimate.
Discovery of previously unknown POAG risk loci in the cross-
ancestry meta-analysis. In the third stage, given the large genetic
correlation between ancestries, we performed a fixed-effect meta-
analysis of the results from stage 1 and 2 (34,179 cases vs. 349,321
controls) and identified 127 independent genome-wide significant
loci, located at least >1 Mb apart (Fig. 3 and Supplementary
Fig. 3). Of these, 44 loci were not previously associated with
POAG at genome-wide significance levels (Supplementary
Data 4). All loci identified in the European meta-analysis were
also significant at the genome-wide level in the combined
ancestry meta-analysis except for three loci, two of which were
not previously identified (OVOL2 and MICAL3), and one pre-
viously reported (EGLN3/SPTSSA). Of note, four of the risk loci
(MXRA5-PRKX, GPM6B, NDP-EFHC2, and TDGF1P3-CHRDL1)
are on the X chromosome, representing the first POAG risk loci
on a sex chromosome. We also identified an association of a
human leukocyte antigen (HLA) gene (HLA-G/HLA-H) with
POAG. All the lead SNPs have MAF > 0.01 in Europeans, except
for two variants: rs74315329 (MAF= 0.0026 in 1000G Eur-
opeans) a well-known nonsense variant in MYOC22,23, and
rs190157577 (MAF= 0.0013 in 1000G Europeans) an intronic
variant in LINC02141/LOC105371299.
The POAG risk loci were strongly replicated in 23andMe. In
the fourth stage, we validated the association of the genome-wide
significant SNPs from stage 3 in a dataset comprising 43,254
participants with self-reported POAG (defined as those who
reported having glaucoma excluding angle-closure glaucoma or
other types of glaucoma) and 1,471,118 controls from 23andMe,
Inc. Of the 127 loci, the association results for 125 SNPs were
available in 23andMe, 120 of which (96%) were replicated at P <
0.05, and 106 (85%) after Bonferroni correction for 125 inde-
pendent tests (Supplementary Data 4). The correlation of the
effect size was r= 0.98 (95% CIs 0.977-0.989). In total, the
genome-wide significant loci in this study (N= 127) collectively
explain 9.4% of the POAG familial risk. The previously known
loci (N= 83) explain 7.5% of the familial risk, and the previously
unreported loci (N= 44) explain an additional 1.9%.
Most of the risk loci associated with POAG involve known
glaucoma-related endophenotypes. Several highly heritable
endophenotypes are related to POAG risk including IOP, struc-
tural variation of the optic nerve characterized as vertical cup-to-
disc ratio (VCDR) and variation in thickness of the retina cell
layers including the retinal nerve fiber layer (RNFL) and the
ganglion cell inner plexiform layer (GCIPL)24.
All POAG risk variants identified to date have also been
associated with either IOP or with VCDR or both. We
investigated the association of the POAG loci identified in this
study with IOP and VCDR, using previous GWAS data for IOP
(N= 133,492)11 and for VCDR (N= 90,939)15. Figure 4a shows
that the majority of loci (89 of 123; four were unavailable for IOP)
are also associated with IOP (red and green dots on Fig. 4a). For
the 34 loci with unclear effect on IOP (purple and blue dots on
Fig. 4a, full data in Supplementary Data 5), we plotted the POAG
effect sizes against VCDR effect sizes and determined that 24 of
the 32 SNPs (2 SNPs unavailable for VCDR), have a clear effect
on VCDR (purple dots on Fig. 4b). Eight of the POAG loci did
not appear to have a clear effect on IOP or VCDR, although a
small effect on glaucoma via a small change in IOP or VCDR
could not be ruled out. The overall correlation of effect sizes
between all POAG risk loci and IOP was 0.53, and between
POAG and VCDR was 0.31, in line with previously published
genetic correlation estimates25. To better visualize clustering of
the POAG SNPs based on their effect on IOP/VCDR, we created
Fig. 2 Correlation of SNP effect estimates between the European POAG
meta-analysis and the replication dataset. The x-axis shows effect
estimates in log(OR) scale for the independent genome-wide significant loci
obtained from the meta-analysis of POAG in Europeans (16,677 POAG cases
vs. 199,580 controls). The y-axis shows the effect estimates in log(OR) scale
for the same SNPs obtained from meta-analysis of the following three GWAS
data: glaucoma self-reports in UKBB, POAG in Asians, and POAG in Africans
(the overall sample size of 17,502 cases and 149,741 controls). Red dots are
the previously identified risk loci and blue dots are the previously unreported
risk loci identified in this study. Horizontal gray bars on each dot represent
the 95% confidence intervals (CIs; mean values+ /− 1.96*SEM) for the
effect estimates in Europeans (from the GWAS meta-analysis of 16,677
POAG cases vs. 199,580 controls), and vertical gray bars shows the 95% CIs
in the replication dataset (from the GWAS meta-analysis of 17,502 POAG
cases vs. 149,741 controls). The blue line is the linear regression line best
fitting the data. The shaded area shows the 95% CIs on the repression line.
UKBB UK Biobank, POAG primary open-angle glaucoma, OR odds ratio.
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a heatmap by clustering SNPs based on Pearson correlation
between effect estimates of SNPs on POAG, IOP, and VCDR
(Supplementary Fig. 4).
Of the 127 POAG genome-wide significant lead SNPs, 116
were available in a GWAS of GCIPL thickness (N= 31,536;
Supplementary Data 6). Of these, 14 loci were associated with
GCIPL thickness at nominal significance threshold (P < 0.05) and
four (PLEKHA7, MAPT, LINC01214-TSC22D2, and POU6F2)
after Bonferroni correction for the number of tests (P < 0.05/116).
Similarly, 13 loci were nominally associated with RNFL, and three
(PLEKHA7, MAPT, and SIX6) after Bonferroni correction. These
results suggest that these loci may impact glaucoma pathogenesis
through modulation of retinal thickness.
Given that three POAG risk loci that we identified (loci
containing MAPT, CADM2, and APP) have also been implicated
in Alzheimer’s disease (AD) and dementia26–28, we asked
whether the same causal variants may underlie these loci and
whether there is evidence for genetic sharing in any of the other
genome-wide significant POAG loci. Applying the Bayesian-
based colocalization method, eCAVIAR29, to the cross-ancestry
and European POAG GWAS meta-analyses and the publicly
available AD GWAS data30 for 21,982 cases and 41,944 controls30
of European descent, we found no evidence for sharing of causal
variants in the 123 (cross-ancestry) or 66 (European) autosomal
POAG loci (Colocalization Posterior Probability (CLPP) < 0.01;
Supplementary Data 7). With a larger AD GWAS meta-analysis
of 71,880 cases and 383,378 controls30,31, there was weak support
for colocalization at six loci (CLPP= 0.01–0.14; four loci from the
cross-ancestry and three from the European POAG meta-analysis
with one overlapping locus; see Supplementary Data 8), though
none of these POAG loci reached genome-wide significance in
the AD GWAS (AD variant P-values on the order of 10−4 to
0.05). We note that the colocalization results with this larger AD
GWAS meta-analysis30,31 might be slightly inflated due to the
large overlap of UK biobank samples between the POAG and AD
meta-analyses. We further estimated the genome-wide genetic
correlation between POAG and AD using LD score regression
(LDSR)32 that adjusts for sample overlap, on the two AD
GWASs;30,31 the correlation estimates were 0.03 (95% CIs:
−0.11–0.16; P= 0.7) and 0.14 (95% CIs: 0.003–0.28; P= 0.049),
respectively.
We next investigated genetic correlation between POAG and a
range of other traits using bivariate LDSR32 through the LD Hub
platform (http://ldsc.broadinstitute.org/ldhub/). Only glaucoma,
self-report glaucoma, and “Other eye problems” were significantly
associated after adjustment for multiple testing for 758 traits (P <
6.6e-05; Supplementary Data 9). Some other traits in UKBB such
as myopia (short-sightedness); systolic blood pressure; seeing a
psychiatrist for nerves, anxiety, tension or depression; and
suffering from nerves, showed some evidence for association at
P < 0.003 (Supplementary Data 9).
Cross-ancestry fine-mapping. Incorporating GWAS data across
European, Asian, and African ancestries allowed us to improve
fine-mapping of the most likely causal variants. For 10 loci
(including previously unidentified loci GJA1/HSF2, SEPT7, and
MXRA5/PRKX), the posterior probability of finding a causal SNP
Fig. 3 Manhattan plots for the cross-ancestry meta-analysis. Each dot represents a SNP, the x-axis shows the chromosomes where each SNP is located,
and the y-axis shows −log10 P-value of the association of each SNP with POAG in the cross-ancestry meta-analysis (34,179 cases vs. 349,321 controls).
The red horizontal line shows the genome-wide significant threshold (P-value= 5e-8; −log10 P-value= 7.30). The nearest gene to the most significant
SNP in each locus has been labeled.
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in Europeans improved after including Asian and African data
(improvements from posterior probabilities <0.9 to >0.9 or from
<0.8 to >0.8; Supplementary Data 10). For eight loci (of which
THRB and SMAD6 were not known), although the posterior
probability of a SNP being causal in Europeans was high (>0.9 at
least for one SNP), there was still a slight improvement after
including the other ancestries (Supplementary Data 10). In con-
trast, the cross-ancestry data made fine-mapping worse for three
loci where the posterior probabilities in Europeans were >0.8 but
declined to <0.8 after incorporating data from the other ances-
tries. For the rest of the loci, the posterior probabilities did not
change significantly after including Asian and African data.
Overall, the best causal SNPs in Europeans changed for 52 of 127
loci after including data from the other ancestries (Supplementary
Data 10). For the remaining 75 loci, at least one SNP remained
the best causal SNP in both fine-mapping using European data
alone, as well as across ancestries, and 23 of the 127 lead SNPs
identified in the meta-analysis remained the best causal SNP in
cross-ancestry fine-mapping.
Gene-based and pathway-based results. We performed gene-
based and pathway-based tests using MAGMA v1.07b33 for each
ancestry separately, followed by combining P-values across
ancestries using Fisher’s combined probability test34. We identi-
fied 205 genes that passed the gene-based Bonferroni-corrected
threshold (P < 0.05/20174), corresponding to an additional seven
independent risk loci located at least >1Mb apart from the risk
loci identified in the single-variant-based test. Supplementary
Data 11 presents significant genes within these seven loci.
Expression of the risk genes identified in MAGMA gene-based
analysis were significantly enriched in artery and nerve tissues,
reflecting the widely recognized neuronal and vascular character
of glaucoma (Supplementary Fig. 5A, B).
Pathway analysis identified 21 significant gene-sets surviving
the Bonferroni-corrected threshold (P < 0.05/10678). These
included previously identified pathways such as collagen forma-
tion and vascular development10,11, and highlighted additional
pathways involved in lipid binding and transportation such as
apolipoprotein binding and negative regulation of lipid storage
(Supplementary Data 12). Genes involved in these pathways that
demonstrated suggestive association (P < 5e-05) with POAG in
the MAGMA gene-based test are summarized in Supplementary
Data 13.
Functional relevance of the identified POAG risk loci. We used
multiple lines of genetic evidence to investigate the functional
relevance of the identified risk loci, and to prioritize causal var-
iants and target genes. A summary of these results for the pre-
viously unknown loci is provided in Table 1, with additional
details presented in Supplementary Data 14. The following
paragraphs describe these findings in further detail.
First, the relevance of the identified risk loci was investigated
by examining their roles in regulation of gene expression, as well
as chromatin interactions. Approximately 76% (96 out of 127) of
the lead SNPs or those in high LD (r2 > 0.8) with the lead SNPs
have also been reported to be significant expression quantitative
trait loci (eQTLs) (FDR < 0.05) in various tissues (Supplementary
Data 14 and 15). Moreover, the identified risk loci have 34,724
unique significant (FDR < 1e-6) chromatin interactions in various
tissues/cell lines involving 4882 genes (Supplementary Fig. 6). Of
these, 425 genes overlap with the eQTL genes (286 genes if only
considering eQTL results for the genome-wide significant SNPs).
Fig. 4 Association of the POAG risk loci with IOP and VCDR. The x-axes show POAG effect estimates in log(OR) scale for the independent genome-wide
significant loci obtained from the cross-ancestry meta-analysis. The y-axes show the effect estimates for the same SNPs obtained from the meta-analysis
of IOP in UKBB+ IGGC (mmHg scale; a) and the meta-analysis of VCDR in UKBB+ IGGC (b). Blue line shows the regression line for IOP (a) and VCDR
loci (b). Orange dots represent SNPs having P < 0.05 for IOP, purple dots P < 0.05 for VCDR, green dots P < 0.05 for both IOP and VCDR, and blue dots
P > 0.05 for both IOP and VCDR. Horizontal gray bars on each dot represent the 95% confidence intervals (CIs; mean values+ /− 1.96*SEM) for the
POAG effect estimates (34,179 cases vs. 349,321 controls), and vertical gray bars shows the 95% CIs for IOP (N= 133,492; a) and VCDR (N= 90,939; b).
The shaded area shows the 95% CIs on the repression line. Although none of the blue dots show an expected trend of association with IOP in a (their 95%
CIs do not overlap with the regression line), the majority of them show a trend of association for VCDR in b. UKBB UK Biobank, IGGC International
Glaucoma Genetics Consortium, IOP intraocular pressure, VCDR, vertical cup-to-disc ratio, POAG primary open-angle glaucoma, OR odds ratio.
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In addition, the lead SNPs or SNPs with LD r2 > 0.8 with the lead
SNPs for 124 risk loci identified in this study overlap with one
end of these chromatin interactions (Supplementary Data 14).
Additional support for the pathogenicity of the POAG risk loci
comes from the predicted pathogenicity scores: 20 SNPs had
CADD scores >12.37, suggesting that these SNPs have deleterious
effects (Supplementary Data 16)35. Overall, three lead SNPs are
protein-altering variants and 12 lead SNP are in high LD
(r2 > 0.8) with a protein-altering variant (Supplementary Data 14),
suggesting pathogenic effects through protein-coding roles of
these variants (e.g., rs61751937 a missense variant in SVEP1). In
addition, 24 SNPs had RegulomeDB36 scores ≤3, supporting
regulatory roles for these SNPs (Supplementary Data 16).
To investigate which risk loci are more likely to affect POAG
by modulating gene expression, we used two transcriptome-wide
association study (TWAS) approaches: Summary Mendelian
randomization (SMR)37 and MetaXcan38. For MetaXcan, we
used our POAG cross-ancestry meta-analysis statistics, RNA-seq
and genotype data from peripheral retina (EyeGEx)39 and 44
GTEX tissues. Following Bonferroni correction for the maximum
number of genes tested (N= 7209) in 45 tissues (P < 1.5e-07), we
identified 100 significant genes, which were selected as the most
likely causal genes based on the integration of eQTL data (also see
below and Supplementary Data 14 and 17). Of these significant
genes, three (AKR1A1, DDIT4L/LAMTOR3, and C4orf29) were
located >1Mb apart from (the other loci) identified using single-
Table 1 Summary of the previously unreported POAG risk loci annotation and functional studies.















rs172531 Intron RERE NO RPL7P11 RERE RERE NO NO RERE NO
rs941125 Intron GLIS1 NO SLC25A3P1 GLIS1 NO NO NO GLIS1 NO
rs4076000 Intergenic ELOCP18/RPE65 NO CTBP2P8 WLS NO NO NO NO NO
rs12566440 Intron GPR88 NO VCAM1 VCAM1 VCAM1 NO NO GPR88 NO
rs4542196 Intron DDR2 NO DDR2 DDR2 NO NO NO NO DDR2
rs12623251 Intergenic TRIB2 YES AC013471.1 TRIB2 NO NO NO TRIB2 NO
rs6713914 Intron LOC105374754 NO AC009970.1 NO NO NO YES NO NO
rs12613800 Intron ZNF638 NO RNU6-105P ZNF638 ZNF638 ZNF638 NO ZNF638 NO
rs9852634 Intron THRB YES RPL31P20 NO NO NO NO NO NO
rs1500708 Intron ARHGEF3 YES ARHGEF3-AS1 NO NO NO NO ARHGEF3-
AS1
NO
rs6437582 Intergenic ALCAM YES AC074043.1 ALCAM ALCAM NO NO NO NO
rs10517281 Intron SCFD2 YES Multiplei FIP1L1 NO NO YES SCFD2 NO
rs57400569 Intron FAM13A YES Multiple FAM13A NO NO YES NO NO
rs17527016 Intergenic PITX2 NO AC083795.1 NO NO NO YES NO PITX2
rs6552711 Intron STOX2 NO ENPP6 NO NO NO NO NO NO
rs407238 Intergenic HLA-G NO Multiple NO NO NO NO Multiple NO
rs3777588 Intron CLIC5 NO MIR4642 CLIC5 CLIC5 NO YES CLIC5 NO
rs7760346 Intergenic GJA1/HSF2 NO Multiple HSF2 Multiple NO NO NO GJA1
rs2811688 Intron SLC2A12 NO TBPL1 SLC2A12 SLC2A12 NO NO SLC2A12 NO
rs2191828 Intron CREB5 NO AC005105.1 NO NO NO NO NO NO
rs6957752 Intergenic SEPT7 NO Multiple RP11-379H18.1 RP11-
379H18.1
NO NO NO NO
rs7805468 Intergenic PCLO/SEMA3E NO AC079799.1 NO NO NO NO SEMA3E SEMA3E
rs2515437 Intron ANGPT2/MCPH1 NO Multiple NO NO ANGPT2 NO NO ANGPT2
rs35740987 Intron GTF2E2 NO Multiple GTF2E2 NO NO NO GTF2E2 NO
rs61751937 Missense SVEP1 NO AL162414.1 NO NO SVEP1 YES NO NO
rs6602453 Intron CELF2 NO AL136369.1 SFTA1P NO NO NO ECHDC3 NO
rs72837408 Downstream MIR4483/
PLEKHS1
NO ADRB1 RP11-211N11.5 NO NO NO Multiple NO
rs7120067 Intron YAP1 NO AP000942.2 YAP1 NO NO NO YAP1 YAP1
rs10444329 Downstream CADM1 NO AP000462.3 CADM1 NO NO NO NO NO
rs7972874 Intergenic PTHLH/CCDC91 NO PTHLH CCDC91 CCDC91 NO NO NO NO
rs4903352 Intron TTLL5 NO TGFB3-AS1 FLVCR2 NO NO NO Multiple TGFB3
rs72692789 Intron SYNE3/SNHG10 NO Multiple NO NO NO NO NO NO
rs2439386 Intron SMAD6 NO NO SMAD6 NO NO NO SMAD6 SMAD6
rs8038628 Intergenic SLCO3A1/SV2B NO SLCO3A1 NO NO NO NO NO NO
rs190157577 Intron LINC02141/
LOC105371299
NO NO NO NO NO YES NO NO
rs242559 Intron MAPT NO Multiple Multiple Multiple Multiple NO Multiple MAPT
rs1348518145 Intron NPEPPS NO KPNB1 NO NO NPEPPS/
TBKBP1
NO NPEPPS NO
rs6124885 Intron EYA2 NO MIR3616 NO NO NO NO NO NO
rs13049669 Intergenic GABPA/APP NO APP MRPL39 NO NO NO NO APP
rs13050568 Intron PSMG1/
LOC107985484
YES RPSAP64 AF064858.11 NO NO NO NO NO
rs12846405 Intergenic MXRA5/PRKX NO MXRA5 MXRA5 NO NO NO MXRA5 Multiple
rs66819623 Intron GPM6B NO AC003035.1 GEMIN8 NO NO NO NO NO
rs17146835 Intergenic NDP/EFHC2 NO AL034370.1 NO NO NO NO NO Multiple
rs12013156 Intergenic TDGF1P3/
CHRDL1
NO NO NO NO NO NO NO CHRDL1
aThis column indicates whether the GWAS lead SNP was identified to be the most probable causal SNP across ancestries in the multi-ethnic fine-mapping analyses performed using the software
PAINTOR.
bWhere the GWAS lead SNP or SNPs in LD r2 > 0.8 with the lead SNP overlap with one end of a chromatin interaction, the most significant gene involved in this interaction has been shown.
cWhere the GWAS lead SNP or SNPs in LD r2 > 0.8 with the lead SNP is an eQTL in any GTEx tissue or the other eQTL databases used in this study (see the Methods), the most significant target gene
has been shown.
dWhere the GWAS lead SNP or SNPs in LD r2 > 0.8 with the lead SNP is an eQLT in retina in EyeGEx study, the most significant target gene has been shown.
eWhere the GWAS lead SNP is a protein-altering variant or in LD r2 > 0.8 with a protein-altering variant, the corresponding gene has been shown.
fThis column indicates whether the GWAS lead SNP has a CADD score > 12.37.
gThis column shows the loci in which one or multiple genes were significant in any of the gene-based tests (MAGMA, MetaXcan, SMR, and FOCUS) used in this study. “Multiple” indicates that several
genes are involved. These genes have been named in Supplementary Data 14.
hThis column shows the loci for which the reported nearest genes or the significant genes identified in the gene-based tests above are members of at least one significant POAG pathway identified in
this study.
i“Multiple” indicates several genes.
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variant and other gene-based tests performed in this study and
were not previously reported for POAG (Supplementary Data 17).
In a post hoc analysis looking solely at retina, two additional
genes (CNTF and MPHOSPH9) were significant (given Bonfer-
roni correction threshold for 6508 genes in retinal tissue).
Additionally, we integrated our GWAS meta-analysis summary
statistics with eQTL data from blood (CAGE eQTL summary
data, N= 2765) and retina (EyeGEx eQTL data, N= 406) using
SMR. Given that these eQTL data were obtained from people of
European descent, we restricted this analysis to our European
meta-analysis to ensure that different gene expression and LD
structure patterns between ancestries did not influence the SMR
findings. In retina and blood, 16 genes passed the SMR
significance threshold corrected for the maximum number
of 8516 genes tested in two tissues (P < 2.9e-06), of which eight
had a P > 0.05 in the heterogeneity in dependent instruments
(HEIDI) test37 implemented in SMR, suggesting that the same
association signals drive both gene expression and POAG risk, at
these loci (Supplementary Data 18). Although the majority of the
risk loci identified through the MetaXcan and SMR approaches
were also identified in the meta-analysis, these analyses help with
prioritizing the most likely functionally relevant genes. To further
identify the most plausible causal genes based on gene expression
data, we used the approach implemented in FOCUS v0.540, a
probabilistic framework that assigns a posterior probability for
each gene causally driving TWAS associations in multiple tissues
(Supplementary Data 19 summarizes the genes with a posterior
probability >0.6).
Integrating data from several lines of evidence described above,
as well as the cross-ancestry fine-mapping and genetic pathways,
provided support for specific genes potentially influencing POAG
risk particularly RERE, VCAM1, ZNF638, CLIC5, SLC2A12,
YAP1, MXRA5, and SMAD6 (Table 1 and Supplementary
Data 14). For example, rs3777588, a lead GWAS SNP in this
study, is an intronic variant within CLIC5. The CADD score for
this variant is 16.58, providing support for the pathogenicity of
this variant (determined by a CADD score > 12.37). The lead SNP
is also an eQLTL for CLIC5 in both GTEx and retina, and gene-
based analysis by incorporating eQTL data supported the
involvement of CLIC5 in POAG risk. This approach also helped
to select best genes near the lead SNPs or to shift the focus from
the nearest genes to genes further away. For example, rs12846405,
a lead GWAS SNP in this study, is an intergenic variant located
between MXRA5 and PRKX. Based on integration of eQTL data
and gene-based analysis, MXRA5 was prioritized as the most
likely causal gene in this locus.
Differential expression of the previously unknown risk loci in
eye tissues. We investigated the expression of the genes nearest to
the lead SNP for the novel loci in 21 healthy eye tissues11 (Sup-
plementary Data 20 and Supplementary Fig. 7). Clustering ana-
lysis shows that the majority of these genes were expressed in eye
tissues (Supplementary Fig. 7A). We examined the differential
expression of the previously unreported genes in ocular tissues
likely to be involved in POAG pathogenesis, namely trabecular
meshwork, ciliary body and optic nerve head, and found 36/51
(71%) of the genes differentially expressed in these tissues com-
pared to the other eye tissues tested in this study (Supplementary
Data 20 and Supplementary Fig. 7B).
Drug targets. At least 16 of the POAG risk genes (nearest to the
lead SNPs) are targeted by existing drugs, some of which are
already in use/clinical trials for several eye or systemic diseases
(Supplementary Data 21). The functional relevance of 14 of these
16 drug target genes is supported by the bioinformatic functional
analyses we used in this study (i.e., eQTL, chromatin interaction,
etc; Supplementary Data 21). We discuss the relevance of some of
these drugs in the discussion section below.
Sex-stratified meta-analysis. We identified a very high genetic
correlation (rg= 0.99, se= 0.06) between POAG in men versus
women (European stage 1 and UKBB self-reports combined). We
also performed cross-ancestry, sex-stratified meta-analyses using
a subset of the overall study with sex-stratified GWAS available
(Supplementary Data 1; Supplementary Data 22 and 23; Sup-
plementary Fig. 1C, D). Only one signal near DNAH6 appeared to
have a female-specific effect (2:84828363[CA], OR= 1.6,
P= 3.28e-09 for women; OR= 1.05, P= 0.56 for men).
Subtype-stratified meta-analysis. Based on IOP levels, POAG
can be classified into two major subtypes: high-tension glaucoma
(HTG) in which IOP is increased (>21 mmHg), and normal
tension glaucoma (NTG) in which IOP remains within the nor-
mal range. We performed cross-ancestry subtype-specific meta-
analyses using 3247 cases and 47,997 controls for NTG (Normal
tension glaucoma defined as glaucoma with IOP < 21 mmHg),
and 5144 cases and 47,997 controls for HTG (high-tension
glaucoma with IOP > 21 mmHg (Supplementary Data 24 and 25
and Supplementary Fig. 1E, F). All NTG and HTG loci were also
significantly associated with the overall POAG meta-analysis
except for one locus near FLNB that was significant for NTG (lead
SNP rs12494328[A], OR= 1.18, P= 1.7e-08), but did not reach
the significance threshold for POAG overall (P= 7.5e-07).
However, this SNP was significant in the 23andMe replication
study (rs12494328[A], OR= 1.06, P= 1.35-e12), and has pre-
viously been associated with optic nerve head changes41. Overall,
all NTG loci were at least nominally associated (P < 0.05) with
HTG (and vice versa) except for rs1812974 (top SNP near
ARHGEF12). Although this SNP had the same direction of effect
for NTG, the effect was significantly larger for HTG than NTG
(P= 0.007). Similarly, several other loci had significantly larger
effects on one subtype (e.g., CDKN2B-AS1, FLNB, and C14orf39
had larger effects on NTG than HTG) (Supplementary Data 24
and 25). Overall, the genetic correlation between NTG and HTG
was estimated to be 0.58 (se= 0.08) using LD score regression
and the meta-analysis summary data from Europeans.
Discussion
In this large multi-ethnic meta-analysis for POAG, we identified
127 risk loci for POAG, of which 44 were not previously iden-
tified. We also identified additional risk loci using gene-based
tests and highlighted genetic pathways involved in the patho-
genesis of POAG. We observed relatively consistent genetic
effects for POAG across ancestries. The risk loci include genes
that are highly expressed in relevant eye tissues, nerves, arteries,
as well as tissues enriched with these components. Functional
relevance of the identified risk loci were further supported by
eQTL and chromatin interaction data.
We identified a significant correlation between the POAG
effect sizes of genome-wide significant SNPs, as well as all the
SNPs throughout the genome, across Europeans, Asians, and
Africans. Although previous studies have suggested that the
genetic architecture of POAG might differ between Africans and
Europeans42, we observed a moderate correlation (r ~ 0.45)
between effect sizes of the POAG risk loci in Europeans and
Africans (Supplementary Fig. 2C), and the correlation was higher
between Europeans and Asians (r ~ 0.7). Although the overall
correlation is moderately high across ancestries, there are geno-
mic regions where the LD pattern differs by ancestry and our
fine-mapping approach showed that incorporating GWAS data
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across ancestries improved the probability of finding a causal
variant for 18 loci in this study, including known (e.g., AFAP1
and RELN loci) and unknown (e.g., GJA1/HSF2 and SEPT7) loci.
However, the most probable causal variants in Europeans
remained the same for ~60% (75 out of 127) of the risk loci even
after incorporating Asian and African GWASs. Overall, due to
the relatively lower statistical power of our African studies, the
fine-mapping results in this study were not strongly influenced by
African GWASs, emphasizing that larger African POAG GWASs
are required for better cross-ancestry fine-mapping in the future.
We also identified a previously unknown association of a
human leukocyte antigen (HLA-G/HLA-H) with POAG. The
HLA system is a gene complex encoding the major histo-
compatibility complex proteins in humans. These cell-surface
proteins are responsible for the regulation of the human immune
system. The most significant SNP in this region (rs407238) has
been associated at the genome-wide significance level for other
traits such as Celiac disease, intestinal malabsorption, disorders of
iron metabolism, multiple blood traits, hyperthyroidism, multiple
sclerosis, hip circumference, and weight (https://genetics.
opentargets.org/variant/6_29839124_C_G). The mechanism of
action of the lead SNP appears to be via IOP (UKBB IOP GWAS
P= 8.8e-06).
The gene-sets enriched for the risk loci identified in this study
indicate two major pathogenic mechanisms for POAG: (1) vas-
cular system defects, mainly the molecular mechanisms con-
tributing to blood vessel morphogenesis, vasculature development,
and regulation of endothelial cell proliferation, and; (2) lipid
binding and transportation—mainly the molecular mechanisms
involved in intracellular lipid transport, apolipoprotein binding,
negative regulation of lipid storage, and positive regulation of
cholesterol efflux. Involvement of the vascular system in the
pathogenesis of POAG is further supported by our results showing
enrichment of the expression of the POAG risk genes in arteries
and vessels. Molecular targets in these pathways can be potential
candidates for treatment of POAG. Two of the significant gene-
sets in this study (phagocytosis engulfment and negative regula-
tion of macrophage derived foam cell differentiation) suggest an
important role of immune system defects in increasing the risk
of POAG.
Integrating several lines of genetic evidence provided support
for specific genes within the identified risk loci that could influ-
ence risk through known and unknown processes. MXRA5 and
SMAD6 are both involved in transforming growth factor (TGF)
beta-mediated extracelluar matrix remodeling43,44, a process
known to contribute to POAG risk45. Additionally, a SVEP1
missense allele was associated with POAG risk (rs61751937).
SVEP1 encodes an extracellular matrix protein that is essential for
lymphangiogenesis in mice, through interaction with ANGPT2
(the product of another POAG risk gene identified in this study),
and modulation of expression of TEK and FOXC2 in knockout
mice46. Lyphangiogenesis has an important role in the develop-
ment of Schlemm’s canal required for outflow of fluid from the
eye47,48, and two other genes necessary for lyphangiogenesis and
Schlemm’s canal development (TEK, ANGPT1) cause childhood
glaucoma49,50. Interestingly, SVEP1 was shown to be a modifier
of TEK-related primary congenital glaucoma51. VCAM1 is an
extracellular matrix cell adhesion molecule involved in angio-
genesis and possibly regulation of fluid flow from the eye52. RERE
mutations are a cause of neurodevelopmental disorders that can
involve the eye53, providing further evidence for a role of ocular
development in adult glaucoma54. While RERE has also been
associated with VCDR55, this is the first association with POAG.
Genes involved in biological processes not previously known to
contribute to glaucoma have also been implicated by this study.
CLIC5 encodes a chloride channel that functions in
mitochondria56 and could have a role in ocular fluid dynamics.
ZNF638 is a zinc finger protein that regulates adipose differ-
entiation57 and has been implicated in the genetic regulation of
height58. SLC2A12 is a glucose transporter that is also involved in
fat metabolism59. YAP1 is an oncogene that is a main effector of
the HIPPO tumor suppressor pathway and apoptosis inhibitor60,
processes that could influence retinal ganglion cell survival in
glaucoma. In mice, heterozygous deletion of Yap1 leads to com-
plex ocular abnormalities, including microphthalmia, corneal
fibrosis, anterior segment dysgenesis, and cataract61.
Several proteins encoded by genes within the identified POAG
risk loci are targets of some currently approved drugs. For
instance, COL4A1 is targeted by ocriplasmin, a collagen hydro-
lytic enzyme that is currently used to treat vitreomacular adhe-
sion (adherence of vitreous to retina). This drug can degrade the
structural proteins including those located at the vitreoretinal
surface62. Clinical trials are in progress to evaluate ocriplasmin
therapy for several eye conditions including macular degenera-
tion, diabetic macular edema, macular hole, and retinal vein
occlusion. Some other drug candidates targeting proteins encoded
by POAG-associated loci are also currently under consideration
for treating dementia and cardiovascular diseases including aci-
tretin, a retinoid receptor agonist targeting RARB, which has been
considered for treatment of AD in ongoing clinical trials. Also,
dipyridamole, a 3′,5′-cyclic phosphodiesterase inhibitor, targets
PDE7B and current clinical trials are testing therapies based on
dipyridamole for diseases such as stroke, coronary heart disease,
ischemia reperfusion injury, and internal carotid artery stenosis.
Given that our pathway analyses highlighted the involvement of
vasculature development and blood vessel morphogenesis in
POAG pathogenesis, dipyridamole could be a potential therapy
for POAG through modulation of blood flow, which can be
defective in POAG63,64. Further studies to confirm the func-
tionality of these POAG risk genes in vivo and in vitro may
support the suitability of repurposing these drugs as alternative
treatments for POAG. Moreover, comprehensive fine-mapping is
required to identify the most likely causal genes that can be tar-
geted by currently approved drugs.
This study has several strengths and limitations. The main
strength includes identification of risk loci contributing to the
development of POAG across ethnic groups, an advance over
prior POAG GWAS that have mainly focused on individuals
from a single ancestry group. We showed that combining GWAS
data across ancestries increases the power of gene mapping for
POAG. Another strength is the integration of GWAS, gene
expression, and chromatin interaction data to investigate the
functional relevance of the identified loci, as well as to identify the
most plausible risk genes.
A limitation of this study is that although the majority of the
cases were clinically confirmed POAG, our data included >7200
glaucoma cases from the UKBB obtained through self-reports.
However, we observed a very high concordance between the
GWAS results for clinically validated cases versus self-report.
Additionally, the vast majority of our results replicated in self-
report data from 23andMe. The second limitation of this study is
its relatively low statistical power for the subtype-specific analyses
(especially for the NTG subset), limiting the ability of this study
to identify subtype-specific loci. Larger NTG GWASs are required
to dissect the genetic heterogeneity between POAG subtypes.
Third, although where possible each participating study adjusted
for the effect of age in their association testing prior to the meta-
analysis, in a subset of studies, cases and controls were not
matched for age and future studies should fully investigate the
effect of the identified risk loci across different age strata, parti-
cularly for loci where certain alleles are strongly associated with
other age-related conditions. Finally, although we investigated the
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functional relevance of the identified risk loci using bioinformatic
analyses, we did not confirm their functionality in vitro and
in vivo. Further studies to investigate the biological roles of these
risk loci with respect to POAG pathogenesis in relevant eye tis-
sues will further shed light on the molecular etiology of POAG.
In conclusion, this study identified a strong cross-ancestry
genetic correlation for POAG between Europeans, Asians, and
Africans, and identified 127 genome-wide significant loci by
combining GWAS results across these ancestries. The cross-
ancestry data improved fine-mapping of causal variants. By
integrating multiple lines of genetic evidence, we implicate pre-
viously unknown biological processes that might contribute to
glaucoma pathogenesis including intracellular chloride channels,
adipose metabolism and YAP/HIPPO signaling.
Methods
Study design and participants. We obtained 34,179 POAG cases and 349,321
controls including participants of European, Asian, and African descent from 21
independent studies across the world. Number of cases and controls, and dis-
tribution of age and sex for each study are summarized in Supplementary Data 1.
The phenotype definition and additional details such as genotyping platforms for
each study are provided in Supplementary Information. For most of the studies, we
restricted glaucoma to POAG based on the ICD9/ICD10 criteria. However, con-
sidering that POAG constitutes the majority of glaucoma cases in Europeans65, we
also included 7286 glaucoma self-reports from UK Biobank to replicate findings
from the ICD9/ICD10 POAG meta-analysis in Europeans and to maximize the
statistical power of the final stage meta-analysis (please see below). Informed
consent was obtained from all the participants, and ethics approval was obtained
from the ethics committee of all the participating institutions.
We performed a four-stage meta-analysis to combine GWAS data from the
participating studies. In the first stage, we conducted a meta-analysis of the POAG
GWAS in Europeans (16,677 POAG cases and 199,580 controls). In the second
stage, we performed independent meta-analyses of POAG GWAS in Asians (6935
cases and 39,588 controls) and in Africans (3281 cases and 2791 controls)
(Supplementary Data 1). As part of the second stage, the Asian and African meta-
data, as well as data from a GWAS of 7286 self-report glaucoma cases and 107,362
controls of European descent from UKBB were used to validate the findings from
the European Caucasian meta-analysis. The UKBB self-report GWAS was
completely independent of the UKBB IC9/ICD10 POAG GWAS; all the UKBB
POAG cases and controls from the first stage, as well as their relatives (Pi hat >0.2),
were removed from the self-report GWAS dataset. In the third stage, we combined
the results from stage 1 and 2 to increase our statistical power to identify POAG
risk loci across ancestries. In the fourth stage we replicated the stage 3 findings in a
dataset from 23andMe.
To investigate sex-specific loci for POAG, we also conducted a meta-analysis of
POAG in males and females separately. For this analysis, we had GWAS data from
a subset of the overall POAG meta-analysis, including 10,775 cases and 123,644
controls for males, and 10,977 cases and 144,606 controls for females
(Supplementary Data 1). Similarly, to identify risk loci for the HTG and NTG
subtypes, we performed a subtype-specific meta-analysis using 3247 NTG cases and
47,997 controls, and 5144 HTG cases and 47,997 controls.
Quality control (QC) and imputation. Study-specific QC and imputation details
have been provided in Supplementary Information. Overall, SNPs with >5%
missing genotypes, minor allele frequency (MAF) < 0.01, and evidence of sig-
nificant deviations from Hardy–Weinberg equilibrium (HWE) were excluded. In
addition, individuals with >5% missing genotypes, one of each pair of related
individuals (detected based on a p-hat > 0.2 from identity by descent calculated
from autosomal markers), and ancestry outliers from each study (detected based on
principal component analysis including study participants and reference samples of
known ancestry) were excluded from further analysis (for more details please see
Supplementary Information).
Imputation for studies involving participants of European descent was
performed in Minimac3 using the Haplotype Reference Consortium (HRC) r1.1 as
reference panel through the Michigan Imputation Server66. However, for a study of
Finnish population (FinnGen study), whole-genome sequence data from 3775
Finnish samples were used as reference panel for better population-specific
haplotype matching, which results in a more accurate imputation. For studies
involving Asian and African participants, imputation was performed using the
1000 Genomes samples of relevant ancestry. SNPs with MAF > 0.001 and
imputation quality scores (INFO or r2) > 0.3 were taken forward for association
analysis.
Association testing. Association testing was performed assuming an additive
genetic model using dosage scores from imputation, adjusting for age, sex, and
study-specific principal components as covariates, using software such as
PLINK266,67, SNPTEST v2.5.168,69, SAIGE v0.36.370, EPACTS v3.2.6 (https://
genome.sph.umich.edu/wiki/EPACTS), and Rvtests v2.0.371. For studies with a
large number of related individuals, mixed-model association testing was per-
formed to account for relatedness between people. For the X chromosome analysis,
we used the following approach to allow for dosage compensation: females were
coded as 0 (homozygous for non-effect allele), 1 (heterozygous), and 2 (homo-
zygous for effect allele) while males were coded as 0 (no effect allele) and 2 (one
effect allele). The covariates were the same as for the association testing for the
autosomes except removing sex.
To confirm the validity of combining GWAS results across populations
comprising different ancestries, we estimated the genome-wide genetic correlation
for POAG between the populations of European, Asian, and African descent
participating in this study. For this purpose, we used Popcorn v0.9.921, a toolset that
provides estimates of genetic correlation while accounting for different genetic effects
and LD structure between ancestries. For this analysis, the LD scores for each
ancestry population were estimated using the 1000G populations (Europeans, Asians,
and Africans), and SNPs were filtered based on the default MAF= 0.05 in Popcorn.
We performed within and between ancestry meta-analyses using a fixed-effects
inverse-variance weighting approach in METAL (the version released on 2011-03-
25)72 using SNP effect point estimates and their standard errors. The presence of
heterogeneity between SNP effect estimates across studies were investigated using
the Cochran’s Q test implemented in METAL. To identify multiple independent
risk variants within the same locus using GWAS summary statistics obtained from
the meta-analysis, we used the Conditional and Joint (COJO) analysis implemented
in GCTA v1.2673. Q–Q and Manhattan plots were created in R-3.2.2, and regional
association plots in LocusZoom v1.474.
We used the univariate LD score regression19 intercept for each study separately
as well as for the meta-analyzed results to ensure that the test statistics did not
include model or structural biases such as population stratification, cryptic
relatedness, and model misspecification. To investigate the genetic correlation
between POAG and AD, we used bivariate LD score regression32 using two large
AD GWAS meta-analyses30,31. To investigate the genetic correlation between
POAG and the other traits, we used bivariate LD score regression through the LD
Hub platform (http://ldsc.broadinstitute.org/ldhub/).
The association of the POAG risk loci identified in this study with its major
endophenotypes, IOP and VCDR, was investigated using summary statistics from a
recent GWAS meta-analysis for IOP (N= 133,492)11 and VCDR (N= 90,939)15.
The variance in the POAG familial risk explained by the loci identified in this
study (N= 127) was calculated based on
P
i 2pi 1 pi
 
β2i =logðλPÞ, where pi and βi
refer to the MAF and the magnitude of association of the i-th SNP, respectively, and
log (λP) is the familial relative risk obtained from observational studies. The estimates
for pi and βi in this study were obtained from UKBB and European POAG meta-
analysis, respectively, and log (λP) was 9.2 estimated in a previous study75.
23andMe replication. We validated the genome-wide significant risk loci from our
cross-ancestry meta-analysis (127 independent SNPs) and subtype analyses (7
independent SNPs) in a subset of 23andMe research participants of European
descent comprising 43,254 POAG cases and 1,471,118 controls. POAG cases were
defined as those who reported glaucoma, excluding those who reported angle-
closure glaucoma or other types of glaucoma. Controls did not report any glau-
coma. Association testing was performed using logistic regression assuming an
additive genetic model, adjusting for age, sex, top five principal components, and
genotyping platform as covariates.
Cross-ancestry fine-mapping. We used PAINTOR v3.076,77 to perform a cross-
ancestry fine-mapping for the 127 risk loci identified in this study. For this analysis,
the GWAS summary statistics for 1Mb either side of the lead risk SNPs were
extracted from European (including UKBB self-reports), Asian, and African meta-
analyses, separately. To account for different LD patterns between ancestries, we
created ancestry-specific LD matrices between SNPs using 1000G phase 3 as a
reference panel. We allowed for the presence of two causal SNPs per locus. To
investigate any advantage of fine-mapping across ancestries, we compared the
posterior probabilities of the prioritized causal SNPs in Europeans separately, as
well as across ancestries, without including any annotation data.
Gene-based and pathway-based tests. Gene-based and gene-set (pathway) based
tests were performed using the approach implemented in MAGMA v1.07b33. We
performed this analysis for each ancestry separately, and the P-values were then
combined across ancestries using Fisher’s combined probability test. The sig-
nificance threshold for gene-based test was set to P < 0.05/20174, and for pathway-
based tests to P < 0.05/10678, accounting for the maximum number of independent
genes/pathways tested. In addition, MAGMA was used to investigate the enrich-
ment of the expression of the significant risk genes in GETX v6 tissues (P < 1e-03
accounting for 53 tissues tested).
To identify loci with effect on POAG risk due to modulation of gene expression,
we also used alternative gene-based tests that integrate GWAS summary statistics
with eQTL data throughout the genome (TWAS-based approaches). For this
purpose, we used MetaXcan v0.3.338, SMR v0.6937, and FOCUS v0.540. MetaXcan
uses GWAS summary statistics to impute the genetic component of gene
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expression in different tissues based on a reference eQTL panel. We used the
EyeGEx eQTL data from retina39, as well as 44 GTEX tissues as reference eQTL
data for this study. The GWAS input for this analysis included the summary
statistics obtained from the cross-ancestry meta-analysis. We set the significance
threshold to Bonferroni-corrected P < 1.5e-07, accounting for the maximum
number of genes tested (N= 7209) in 45 tissues. To investigate the probability of
each gene causally driving TWAS associations, we used the approach implemented
in FOCUS40, a probabilistic framework that assigns a posterior probability to each
gene. We used the gene expression reference weights provided in FOCUS, which
combines the expression weights obtained from GTEX tissues with the weights
provided in FUSION78 obtained from several tissues, including adipose, peripheral
blood, whole blood, and brain.
SMR uses a Mendelian Randomization framework to identify genes whose
expression is likely modulated through the same variants associated with the
outcome of interest (POAG). For the SMR analysis, we used the following eQTL
data: CAGE eQTL summary data from blood (N= 2765) and EyeGEx eQTL data
from retina (N= 406). The SMR significance threshold was set to P < 2.9e-06,
accounting for the maximum number of 8516 genes tested in two tissues. A
heterogeneity P > 0.05 from the HEIDI test implemented in SMR implies that we
cannot reject the null hypothesis that a single causal variant is likely to affect both
gene expression and POAG risk for these loci.
Gene expression. RNA was extracted from the corneal layers, trabecular mesh-
work, ciliary body, retina, and optic nerve tissues from 21 healthy donor eyes of 21
individuals. After quality control, the RNA was sequenced using Illumina NextSeq®
500 (San Diego, USA). Trimgalore (v0.4.0) was used to trim low-quality bases
(Phred score < 28) and reads shorter than 20 bases after trimming were discarded.
Data analysis was done with edgeR (version 3.22.5)79. Only genes expressed a
minimum of 10 times (1.5 counts per million) in at least five dissected tissues were
kept. The RNA count libraries were normalized using trimmed mean of M-values
method80. Two-group differential expression analysis was done via negative
binomial generalized linear model in edgeR81. The RNA expression in ciliary body,
trabecular meshwork, and optic nerve head, which are involved in aqueous pro-
duction, drainage and principal site of glaucoma injury, respectively, was compared
to the remaining eye tissues.
Drug targets. We used Open Targets82 to search for drugs currently in use or in
clinical trials for treating other ocular or systemic diseases that target the POAG
risk genes identified in this study. These drugs can be potentially repurposed as
alternative treatments for POAG, owing to in vivo and in vitro confirmation of the
functionality of the target genes in the pathogenesis of POAG.
Bioinformatic functional analyses. The bioinformatic functional analysis to inves-
tigate the functional relevance of the identified risk loci for POAG were performed
through the FUMA platform v1.3.583 using the following dataset/toolsets: GTEX eQTL
v684; Blood eQTL browser85; BIOS QTL Browser86; BRAINEAC87; RegulomeDB
v1.136; CADD v1.435; ANNOVAR (the version released on 2016Feb01)88; and Hi-C
data from 21 tissue/cell types (GEO accession: GSE87112)89, PsychENCODE90,
Giusti-Rodriguez et al. (2019)91, and FANTOM5 Human Enhancer Tracks (http://
slidebase.binf.ku.dk/human_enhancers/presets).
Colocalization analysis. To test whether the POAG loci tag a shared causal variant
or haplotype with Alzheimer’s disease (AD), given that several loci overlap, we
applied the bayesian-based colocalization method, eCAVIAR v2.0.029 to all 123
and 66 autosomal POAG significant variants from the cross-ancestry and European
subset POAG GWAS meta-analyses, respectively, and the AD GWAS meta-
analysis from Kunkle et al.30,31 and Jansen et al.31 that lack summary statistics for
chromosome X. Loci were defined by identifying the outermost variant on either
side of each lead POAG variant corresponding to r2 > 0.1 relative to the POAG
variant with an added 50 kb on either side. We used the default parameters of
eCAVIAR (http://genetics.cs.ucla.edu/caviar/manual.html), assuming up to two
causal variants per locus. We used the European derived samples from 1000
Genome Project Phase 3 as the reference panel to compute the LD matrix between
all variant pairs within each locus needed in eCAVIAR, since both AD GWAS
meta-analyses consisted of samples from European ancestry. We used a colocali-
zation posterior probability (CLPP) above 0.01 as the significance cutoff as
recommended by the tool29.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The GWAS summary statistics generated in this study are available via GWAS Catalog
under study accession identifiers GCST90011766, GCST90011767, GCST90011768,
GCST90011769, GCST90011770. UK Biobank data, including POAG, VCDR, IOP,
RNFL, and GCIPL GWASs are available by request through the UK Biobank Access
Management System https://www.ukbiobank.ac.uk/. The GWAS result from 23andMe
are available by request from https://www.23andme.com/. Restrictions apply to the
availability of these data (please see https://www.ukbiobank.ac.uk/principles-of-access/
and https://research.23andme.com/dataset-access/), which were used under license for
the current study, and so are not publicly available. The GWAS results for Alzheimer’s
disease that we used for this study are available from https://ctg.cncr.nl/software/
summary_statistics, and by request from https://www.niagads.org/datasets/ng00075. The
Haplotype Reference Consortium (HRC) r1.1 is accessible by request from https://www.
ebi.ac.uk/ega/studies/EGAS00001001710. Data access requests are reviewed by the Data
Access Committee at Wellcome Trust Sanger Institute. This resource can be used for
imputation without direct access to the raw data through Michigan Imputation server
(https://imputationserver.sph.umich.edu/index.html#!) and Sanger Imputation Service
(https://imputation.sanger.ac.uk/). We used HRC r1.1 for imputation through the
Michigan Imputation server. The 1000 Genomes phase 3 data is available at https://www.
internationalgenome.org/. The datasets we used for the functional analyses in this study
are available through: GTEX eQTL v6 (https://gtexportal.org/home/), Blood eQTL, BIOS
QTL, EyeGEx data (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115828),
BRAINEAC, Hi-C data from 21 tissue/cell types under GEO accession GSE87112,
PsychENCODE, Giusti-Rodriguez et al. (2019) (https://www.biorxiv.org/content/
10.1101/406330v2), and FANTOM5 Human Enhancer Tracks http://slidebase.binf.ku.
dk/human_enhancers/presets. These datasets were used through the FUMA platform
(https://fuma.ctglab.nl/). The drug target data was obtained through the Open Targets
platform (https://genetics.opentargets.org/).
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